Please login to the form below

gout

This page shows the latest gout news and features for those working in and with pharma, biotech and healthcare.

Roche enters NASH race with deal to buy Jecure

Feldstein – sits apart from rival therapies and could have applications beyond NASH in other inflammatory disorders gout including inflammatory bowel disease and cardiovascular diseases.

Latest news

Sanofi’s rare blood disorder drug Cablivi set for European approval

In addition to the orphan drug approvals, the CHMP also gave positive opinions to Gruenenthal’s gout treatment Duzallo (lesinurad/allopurinol), a follow-up to the company’s Zurampic (lesinurad) product.
Daily Brief: EULAR kicks off, Brexit lurches closer and Autolus prepares for IPO

On today’s agenda expect new trial data from Novartis' Ilaris in gout, Lilly's Oluminant in systemic lupus and AbbVie's new JAK inhibitor upadacitinib.
Ironwood claims FDA OK for former AZ gout drug

The US FDA has approved Ironwood Pharma's combination gout therapy Duzallo, but with a warning that it can cause serious kidney failure. ... Gout is a painful form of inflammatory arthritis caused by elevated levels of uric acid (UA) in the blood, and
Grünenthal buys Zomig rights as AZ slimming drive continues

AstraZeneca has sold a raft of older or non-core products over the past two years, including a $230m deal with Grünenthal for gout drug Zurampic.
Turning healthcare on its head

A good example of this is a recent crowdsourcing campaign designed to generate patient insight to inform gout education. ... The gout crowdsourcing project demonstrated how patients not only valued their interaction with pharma, but that they also learnt

More from news
Approximately 9 fully matching, plus 37 partially matching documents found.

Latest Intelligence

Grünenthal's relentless pursuit of relief

We are involved in projects that go beyond pain - backed by our licence agreement with AstraZeneca for Zurampic in gout, a condition that causes joint pain flares and is diagnosed both
Deal Watch January 2017

230. Cymabay. Kowa. Exclusive licence in the US. Arhalofenate for gout p3 ready.
Deal Watch October 2016

Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.
Deal Watch June 2016

Zurampic, a Selective Uric Acid Reabsorption Inhibitor (SURI), works selectively to complement xanthine oxidase inhibitors (XOIs) in the treatment of hyperuricaemia associated with uncontrolled gout, and was approved by the EMA ... licence. 270.
Deal Watch April 2016

Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 450. AstraZeneca (UK). Ironwood (US). US license and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

THE OTHER SIDE OF … GOUT

She also has gout, an inflammatory condition that affects one in 40 adults in the UK and is on the rise. ... Could these low goals for treatment, alongside the hard-to-shift perception of gout, mean that doctors are not motivated to change their behaviour
Patient Perspective: Gout

What is it like to live with gout? In our latest Patient Perspective interview, we talk to Graham Lewington, who has lived with this form of arthritis for over 25 years. ... Listen to a first-hand account of the symptoms of gout, and how Graham manages

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Account Manager / Senior Account Manager: 35, 000-40, 000

Associate Director: £75, 000-90, 000

Account Director – Health Policy – Global Agency: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Global Business Development Director – Health Education: excellent commission

Senior Medical Writer: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Manager / Account Director: Competative

Medical Writer: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director, Medical Education: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...